In conclusion, the study highlights the role of LINC00330 as a key inhibitor in the development of ESCC and demonstrates its ability to inhibit tumor progression both in vitro and in vivo, suggesting its potential as a therapeutic target and biomarker for ESCC treatment. This evidence concerns the gene LINC00330 and esophageal squamous cell carcinoma.